Circulating microRNA expression profiles associated with systemic lupus erythematosus.

OBJECTIVE To evaluate the specificity of expression patterns of cell-free circulating microRNAs (miRNAs) in systemic lupus erythematosus (SLE). METHODS Total RNA was purified from plasma, and 45 different specific, mature miRNAs were determined using quantitative reverse transcription-polymerase chain reaction assays. A total of 409 plasma samples were obtained from 364 different patients with SLE, healthy control subjects, and control subjects with other autoimmune diseases. The results in the primary cohort of 62 patients with SLE and 29 healthy control subjects were validated in 2 independent cohorts: a validation cohort comprising 68 patients with SLE and 68 healthy control subjects, and a disease control cohort comprising 20 patients with SLE (19 of whom were from the other validation cohort), 46 healthy control subjects, 38 patients with vasculitis, 18 patients with rheumatoid arthritis, and 20 immunosuppressed patients. RESULTS Seven miRNAs were statistically significantly differentially expressed in plasma from patients with SLE. The expression of miRNA-142-3p (miR-142-3p) and miR-181a was increased, and the expression of miR-106a, miR-17, miR-20a, miR-203, and miR-92a was decreased. In addition, the expression of miR-342-3p, miR-223, and miR-20a was significantly decreased in SLE patients with active nephritis. A predictive model for SLE based on 2 or 4 miRNAs differentiated patients with SLE from control subjects (76% accuracy) when validated independently (P < 2 × 10(-9) ). Use of the 4-miRNA model provided highly significant differentiation between the SLE group and disease controls, except for those with vasculitis. CONCLUSION Circulating miRNAs are systematically altered in SLE. A 4-miRNA signature was diagnostic of SLE, and a specific subset of miRNA profiles was associated with nephritis. All of the signature miRNAs target genes in the transforming growth factor β signaling pathways. Other targets include regulation of apoptosis, cytokine-cytokine receptors, T cell development, and cytoskeletal organization. These findings highlight possible dysregulated pathways in SLE and suggest that circulating miRNA patterns distinguish SLE from other immunoinflammatory phenotypes.

[1]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[2]  D. Bartel,et al.  MicroRNAs Modulate Hematopoietic Lineage Differentiation , 2004, Science.

[3]  L. Rönnblom,et al.  Regulation of the interferon-alpha production induced by RNA-containing immune complexes in plasmacytoid dendritic cells. , 2009, Arthritis and rheumatism.

[4]  A. Schetter,et al.  Circulating micro‐RNA expression profiles in early stage nonsmall cell lung cancer , 2012, International journal of cancer.

[5]  P. Gregersen,et al.  The emerging role of interferon in human systemic lupus erythematosus. , 2004, Current opinion in immunology.

[6]  Y. Inoue,et al.  Circulating miR‐142‐3p levels in patients with systemic sclerosis , 2012, Clinical and experimental dermatology.

[7]  Marc Monestier,et al.  Microparticles as antigenic targets of antibodies to DNA and nucleosomes in systemic lupus erythematosus. , 2011, Journal of autoimmunity.

[8]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[9]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[10]  Nan Shen,et al.  miR-155 and its star-form partner miR-155* cooperatively regulate type I interferon production by human plasmacytoid dendritic cells. , 2010, Blood.

[11]  L. Rönnblom,et al.  C1q inhibits immune complex-induced interferon-alpha production in plasmacytoid dendritic cells: a novel link between C1q deficiency and systemic lupus erythematosus pathogenesis. , 2009, Arthritis and rheumatism.

[12]  S. Gay,et al.  The release of microparticles by apoptotic cells and their effects on macrophages , 2005, Apoptosis.

[13]  C. Johnsen,et al.  Distinct features of circulating microparticles and their relationship to clinical manifestations in systemic lupus erythematosus. , 2011, Arthritis and rheumatism.

[14]  Wentian Li,et al.  Elevated Serum Levels of Interferon-Regulated Chemokines Are Biomarkers for Active Human Systemic Lupus Erythematosus , 2006, PLoS medicine.

[15]  S. Salah,et al.  Expression signature of microRNA-181-a reveals its crucial role in the pathogenesis of paediatric systemic lupus erythematosus. , 2011, Clinical and experimental rheumatology.

[16]  D. Gladman,et al.  The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[17]  L. Rönnblom,et al.  Type I interferon and lupus , 2009, Current opinion in rheumatology.

[18]  L. Rönnblom,et al.  Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. , 2004, Arthritis and rheumatism.

[19]  C. Lutz,et al.  Cutting Edge: MicroRNA-181 Promotes Human NK Cell Development by Regulating Notch Signaling , 2011, The Journal of Immunology.

[20]  Lin He,et al.  Molecular dissection of the miR-17-92 cluster's critical dual roles in promoting Th1 responses and preventing inducible Treg differentiation. , 2011, Blood.

[21]  L. Truedsson,et al.  Platelet transcriptional profile and protein expression in patients with systemic lupus erythematosus: up-regulation of the type I interferon system is strongly associated with vascular disease. , 2010, Blood.

[22]  E. Kroh,et al.  Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma , 2011, Proceedings of the National Academy of Sciences.

[23]  C. Lau,et al.  Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus. , 2003, Arthritis and rheumatism.

[24]  A. Divekar,et al.  Dicer Insufficiency and MicroRNA-155 Overexpression in Lupus Regulatory T Cells: An Apparent Paradox in the Setting of an Inflammatory Milieu , 2011, The Journal of Immunology.

[25]  E. Kroh,et al.  Blood Cell Origin of Circulating MicroRNAs: A Cautionary Note for Cancer Biomarker Studies , 2011, Cancer Prevention Research.

[26]  Mark M. Davis,et al.  miR-181a Is an Intrinsic Modulator of T Cell Sensitivity and Selection , 2007, Cell.

[27]  D. Sackett,et al.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.

[28]  R. Voll,et al.  Removal of dying cells and systemic lupus erythematosus , 2005, Modern rheumatology.

[29]  Wu-xian Li,et al.  Circulating microRNAs as candidate biomarkers in patients with systemic lupus erythematosus. , 2012, Translational research : the journal of laboratory and clinical medicine.

[30]  Q. Lu,et al.  Decreased microRNA-142-3p/5p expression causes CD4+ T cell activation and B cell hyperstimulation in systemic lupus erythematosus. , 2012, Arthritis and rheumatism.

[31]  A. Schetter,et al.  Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. , 2010, Carcinogenesis.

[32]  B. Sundaram,et al.  Type I Interferons Are Associated with Subclinical Markers of Cardiovascular Disease in a Cohort of Systemic Lupus Erythematosus Patients , 2012, PloS one.

[33]  K. Vickers,et al.  MicroRNAs are Transported in Plasma and Delivered to Recipient Cells by High-Density Lipoproteins , 2011, Nature Cell Biology.

[34]  P. Tak,et al.  MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. , 2009, Arthritis and rheumatism.

[35]  Igor M. Dozmorov,et al.  Identification of Unique MicroRNA Signature Associated with Lupus Nephritis , 2010, PloS one.

[36]  J. Lötvall,et al.  Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells , 2007, Nature Cell Biology.

[37]  D. Baltimore,et al.  NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses , 2006, Proceedings of the National Academy of Sciences.

[38]  A. Koch,et al.  Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis. , 2012, Arthritis and rheumatism.

[39]  G. Rousseau,et al.  Existence of a microRNA pathway in anucleate platelets , 2009, Nature Structural &Molecular Biology.

[40]  M. Michael,et al.  Prox1 expression is negatively regulated by miR-181 in endothelial cells. , 2010, Blood.

[41]  Yong Dai,et al.  Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients , 2009, Rheumatology International.

[42]  G. Sturfelt,et al.  Induction of apoptosis in monocytes and lymphocytes by serum from patients with systemic lupus erythematosus − an additional mechanism to increased autoantigen load? , 2004, Clinical and experimental immunology.

[43]  Carlo M. Croce,et al.  MicroRNAs 17-5p–20a–106a control monocytopoiesis through AML1 targeting and M-CSF receptor upregulation , 2007, Nature Cell Biology.

[44]  Aikaterini S. Papadopoulou,et al.  The thymic epithelial microRNA network elevates the threshold for infection-associated thymic involution via miR-29a mediated suppression of the IFN-α receptor , 2011, Nature Immunology.

[45]  Lin He,et al.  mir-17-92, a cluster of miRNAs in the midst of the cancer network. , 2010, The international journal of biochemistry & cell biology.

[46]  Lianbo Yu,et al.  Detection of microRNA Expression in Human Peripheral Blood Microvesicles , 2008, PloS one.

[47]  Z. Xu,et al.  Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients , 2007, Lupus.

[48]  N. Shen,et al.  Evidence for microRNA-mediated regulation in rheumatic diseases , 2009, Annals of the rheumatic diseases.